Business Context and Reporting Period
This Form 8-K Current Report from Matinas Biopharma Holdings, Inc. covers the Annual Meeting of Stockholders held on November 1, 2018. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results rather than financial performance.
Material Changes
No material financial changes are reported in this document. The primary events are the election of directors and the ratification of the independent auditor.
Guidance, Outlook, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future operations. It details the final vote tabulations for two proposals:
- Proposal 1: Election of Directors. Stockholders elected seven individuals to the Board of Directors to serve until the 2019 annual meeting. All nominees received significant "For" votes (ranging from approximately 30.7 million to 30.8 million) with minimal "Withheld" votes.
- Proposal 2: Ratification of Auditors. Stockholders approved the appointment of EisnerAmper LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2017. The vote was 75,387,058 "For" versus 678,162 "Against."
Important Facts for Investors to Verify
- Confirm the tenure of the newly elected board members (Herbert Conrad, Patrick LePore, Jerome D. Jabbour, Eric Ende, James Scibetta, Adam Stern, and Matthew Wikler) through the 2019 annual meeting.
- Verify the engagement of EisnerAmper LLP for the fiscal year ending December 31, 2017, as ratified by shareholders.
- Note that this filing does not contain financial data; refer to the company's 10-K or 10-Q filings for financial metrics.